LD-2 disclosure · 2nd Quarter - Report

ALLIANCE FOR REGENERATIVE MEDICINE

2nd Quarter (Apr 1 - June 30) · 2025Posted Jul 23, 2025Filing document ↗LDA record ↗

Expenses$160Kself-filed spend

Client

Name: ALLIANCE FOR REGENERATIVE MEDICINE
Description: Advocacy organization supporting advances in regenerative medicine.
Location: District of Columbia · United States of America

1 issue

Health Issues
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value-based payment legislation and related CMS regulations. FDA appropriations and staffing. Biologics regulation. Prescription Drug User Fee Act (PDUFA). Medicaid. Medicare. (MVP) Act. Accelerating Kids Access to Care Act (S. 752 / H.R.1509). Give Kids a Chance Act (S. 932 / H.R. 1262). Rare Pediatric Disease Priority Review Vouchers. Bipartisan Health Care Act (S. 891). MVP Act (S.1637). NIH appropriations. HHS oversight. HHS staffing and OPM issues. Medical research. Pharmaceutical tariffs. Biotechnology manufacturing.
LobbyistsERICA CISCHKE
TargetedSENATE · HOUSE OF REPRESENTATIVES · Health & Human Services, Dept of (HHS) · Food & Drug Administration (FDA) · Centers For Medicare and Medicaid Services (CMS) · Natl Institutes of Health (NIH)

LD-2 disclosure · 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) · 2025Posted Jul 23, 2025Filing document ↗LDA record ↗

Expenses$160Kself-filed spend

Name: ALLIANCE FOR REGENERATIVE MEDICINE
Description: Advocacy organization supporting advances in regenerative medicine.
Location: District of Columbia · United States of America

1 issue

Health Issues
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value-based payment legislation and related CMS regulations. FDA appropriations and staffing. Biologics regulation. Prescription Drug User Fee Act (PDUFA). Medicaid. Medicare. (MVP) Act. Accelerating Kids Access to Care Act (S. 752 / H.R.1509). Give Kids a Chance Act (S. 932 / H.R. 1262). Rare Pediatric Disease Priority Review Vouchers. Bipartisan Health Care Act (S. 891). MVP Act (S.1637). NIH appropriations. HHS oversight. HHS staffing and OPM issues. Medical research. Pharmaceutical tariffs. Biotechnology manufacturing.
LobbyistsERICA CISCHKE
TargetedSENATE · HOUSE OF REPRESENTATIVES · Health & Human Services, Dept of (HHS) · Food & Drug Administration (FDA) · Centers For Medicare and Medicaid Services (CMS) · Natl Institutes of Health (NIH)